Author

admin

Browsing

Micron Technology (NASDAQ:MU) announced a US$7 billion investment to build a high-bandwidth memory (HBM) chip-packaging facility in Singapore to meet rising global demand for artificial intelligence (AI) technology.

The facility, which will be adjacent to the US-based semiconductor manufacturer’s existing manufacturing site in Singapore, broke ground this week and is scheduled to begin operations by 2026.

Designed to enhance the company’s advanced chip-packaging capabilities, the plant is expected to create 1,400 jobs initially, with the potential to generate up to 3,000 positions as operations scale by 2027.

In a Wednesday (January 8) announcement, Sanjay Mehrotra, Micron’s president and CEO, emphasized the growing demand for memory and storage solutions as AI adoption accelerates across industries.

“With the continued support of the Singapore government, our investment in this HBM advanced packaging facility strengthens our position to address the expanding AI opportunities ahead,” Mehrotra commented.

Singapore continues to strengthen its position as a hub for semiconductor innovation and AI-driven technologies.

The city-state has attracted significant attention from major tech players, with Google (NASDAQ:GOOGL) and Amazon (NASDAQ:AMZN) expanding their cloud and data center infrastructure in the region.

Singapore has become a focal point for global semiconductor production, and its government has supported these initiatives, recognizing the semiconductor sector as vital to the country’s economy.

For instance, NXP Semiconductors (NASDAQ:NXPI) and a firm backed by Taiwan Semiconductor Manufacturing Company (NYSE:TSM,TPE:2330) are currently constructing a US$7.8 billion wafer plant in the country.

Micron’s Singapore strategy complements its work in other parts of Asia, including a US$603 million chip-packaging facility in Xi’an, China, and an US$825 million assembly and testing plant in Gujarat, India, both announced in mid-2023.

The new facility will focus on packaging HBM chips, which are critical to high-performance computing systems like AI data centers. These chips are designed to handle large amounts of data at high speeds.

The Singapore facility is Micron’s first advanced HBM chip-packaging plant in the country.

This past December, the company also finalized a US$6.165 billion subsidy with the US Department of Commerce to bolster domestic semiconductor production under the CHIPS and Science Act.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Iran unveiled an underground missile storage facility and announced Friday that it is manufacturing “new special missiles,” according to Islamic Revolutionary Guard Corps (IRGC) affiliated Tasnim news.

Video released on Iranian state TV IRIB on Friday showed IRGC Commander Major General Hossein Salami and Brigadier General Amir Ali Hajizadeh touring the facility.

Hajizadeh called the site a “dormant volcano,” Tasnim reports.

Part of Iran’s operations against Israel in October and April were carried out using this underground missile base, semi-official Iranian media outlet Mehr News reports.

At an event in Iran’s southwestern city of Abadan on Friday, Salami also announced the IRGC Aerospace Force is developing “new special missiles.”

On Monday, General Ali Mohammad Naeini warned Iran will be holding new drills and war games this month that would reveal “missile and drone cities” including an underground city storing missiles and another facility accommodating vessels in the south of Iran, Tasnim reported.

On Friday, Iranian Basij (volunteer) forces held a large-scale exercise involving 110,000 members in the capital, Tehran, Tasnim reports, adding that the Iranian Armed Forces have held several war games in recent days.

Iran aims to project that it has not lost power in the region, despite Iranian backed forces in Lebanon, Gaza and Yemen coming under attack by Israel and the fall of Syrian leader Bashar al-Assad’s regime, an ally of Iran.

“Our deterrence has not been designed on the basis of action from any other country,” Salami said Friday.

In October, Israel said it struck Iranian missile manufacturing sites and aerial defense systems inside Iran in response to earlier strikes launched by Iran on Israel.

At the time, Iran’s foreign ministry called Israel’s strikes a “clear violation” of international law, adding that it is “entitled and obligated to defend itself.”

The US is just days away from swearing in US President-elect Donald Trump, who previously launched a “maximum pressure” campaign on Iran in his first term. US officials have expressed optimism in negotiations on the Israel-Hamas ceasefire deal with hopes of reaching one before Trump takes office on January 20.

This post appeared first on cnn.com

Brazil’s government will give Meta until Monday to explain the changes to its fact-checking program, Solicitor General Jorge Messias said on Friday.

The move comes after the social media company scrapped its US fact-checking program and reduced curbs on discussions around topics such as immigration and gender identity.

It is not immediately clear exactly what will happen after the deadline expires.

“I’d like to express the Brazilian government’s enormous concern about the policy adopted by the Meta company, which is like an airport windsock, changing its position all the time according to the winds,” Messias, the government’s top lawyer, told reporters in Brasilia.

“Brazilian society will not be at the mercy of this kind of policy,” Messias added.

On Thursday, Brazilian President Luiz Inacio Lula da Silva said the changes were “extremely serious” and announced he had called a meeting to discuss the topic.

Meta did not immediately respond to a request for comment.

In announcing the move on Tuesday, CEO Mark Zuckerberg cited “too many mistakes and too much censorship.” A spokesperson said on Tuesday that, for now, Meta was planning the changes only for the US market.

Reuters, which was a Meta partner on its US fact-checking program, has declined to comment.

This post appeared first on cnn.com

China’s Zijin Mining Group (OTC Pink:ZIJMF,SHA:601899) is reportedly in negotiations to acquire a potential controlling interest in Zangge Mining (SZSE:000408), a Chinese lithium producer.

According to Bloomberg, Zijin Mining is looking to purchase stakes from Zangge Mining’s two largest shareholders, Tibet Zangge Venture Capital and Ningbo Meishan Bonded Port Area Xinsha Hongyun Investment Management. Together, they control approximately 40 percent of Zangge Mining, which is valued at 46.6 billion yuan (US$6.4 billion).

Zangge Mining primarily produces potash for fertilizer, but derives around a third of its revenue from lithium extraction. Its lithium operations focus on salt lake brines in Qinghai, China’s mineral-rich western region.

Zangge Mining reported production of 9,278 metric tons of lithium carbonate in the first nine months of 2024.

Zijin Mining, a producer of copper and gold, has been expanding aggressively, with Chairman Chen Jinghe overseeing its transformation from a gold miner in Southeastern China to a global leader in resource extraction.

Acquiring a stake in Zangge Mining would boost Zijin Mining’s position in the lithium market while enhancing its control over the Julong copper project in Tibet, a joint venture between the two companies. Last year, they secured regulatory approval to increase Julong’s output to 350,000 metric tons per day, establishing it as China’s largest single copper mine.

Beyond China, Zijin Mining is also advancing lithium projects abroad.

The company plans to start lithium production in the Democratic Republic of Congo in 2026, although it has postponed the start of its Argentina and Tibet projects to 2025 due to weak lithium prices and permitting delays.

The company’s strategic plan aims for annual production capacity of up to 300,000 metric tons of lithium by 2028. While its current output is limited, the acquisition of Zangge Mining could accelerate its progress toward that target.

Discussions are ongoing and are subject to agreement terms, board approval and regulatory compliance.

Lithium industry M&A heating up

Zijin Mining’s interest in Zangge Mining is part of a trend toward lithium M&A activity.

Major players like Rio Tinto (ASX:RIO,NYSE:RIO,LSE:RIO) have also pursued acquisitions in the lithium space, evidenced by Rio’s US$6.7 billion agreement to acquire Arcadium Lithium (NYSE:ALTM,ASX:LTM) last year.

Lithium remains a critical component in the transition to clean energy, and companies like Zijin Mining are leveraging their expertise in resource development to capture market opportunities.

The lithium market has experienced significant volatility since late 2022, with prices plummeting nearly 90 percent from their peak. However, this downturn in the industry has created opportunities for acquisitions as producers seek to consolidate and optimize operations amid weaker financial conditions.

By expanding its lithium footprint, Zijin Mining is positioning itself to play a key role in the global energy transition.

Zijin Mining is expected to release more details on the potential acquisition in the coming months.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Endeavour Silver (TSX:EDR,NYSE:EXK) shared its 2024 production results, reporting output for the period of 4,471,824 ounces of silver and 39,047 ounces of gold, or 7.6 million silver equivalent ounces.

The company met its updated annual production guidance, which it adjusted following operational challenges.

‘After operating at reduced capacity due to the Guanaceví trunnion failure in August, and subsequently resuming full capacity in December, we are satisfied with our production performance in Q4 and producing at the top range of our updated production guidance,’ CEO Dan Dickson said in Thursday’s (January 9) press release.

During Q4, Endeavour produced 824,529 ounces of silver and 9,075 ounces of gold, amounting to 1.6 million silver equivalent ounces. Production was lower during the period due to the trunnion failure at Guanaceví in August.

The trunnion was replaced by late November, and full production capacity was restored in December.

The Guanaceví mine operated at reduced capacity for 15 weeks, averaging only 620 metric tons per day due to the trunnion failure. By December, the plant had returned to its designed throughput of 1,200 metric tons per day.

Meanwhile, steady operations at Bolañitos contributed 105,732 silver ounces and 6,453 gold ounces in Q4. The mine’s gold output exceeded projections due to higher grades, while its silver output remained below plan due to lower grades.

Endeavour’s consolidated production for 2024 reflects an 11 percent decrease in processed throughput compared to 2023. Silver output dropped by 21 percent, while gold production saw a 3 percent increase.

The company sold 4,645,574 silver ounces and 38,522 gold ounces during the year.

In recent financial developments, Endeavour secured US$73 million through a bought-deal financing in November.

The proceeds are designated for general working capital and for advancing the Pitarrilla project.

In 2025, the company will focus on strengthening its production pipeline while managing risks and costs. The restoration of full production capacity at Guanaceví is expected to support steady output in 2025. Progress continues at Endeavour’s development projects, including the Pitarrilla mine in Mexico, which remains a strategic priority.

Shares of Endeavour are up nearly 100 percent year-on-year, but traded lower this week. The company closed Thursday at C$5.21 on the TSX and opened Friday (January 10) at US$3.60 on the NYSE. American markets were closed Thursday.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Investor Insight

Radiopharm Theranostics represents a promising investment opportunity in the rapidly growing field of radiopharmaceuticals, leveraging its innovative technology platform and diverse clinical pipeline.

Overview

Radiopharm Theranostics (ASX:RAD) is an innovative biopharmaceutical company specializing in the development of radiopharmaceutical products for both diagnostic and therapeutic applications. Founded with a mission to address significant unmet medical needs, particularly in oncology, the company has positioned itself at the forefront of the rapidly evolving field of precision medicine.

Radiopharm Theranostics innovative technology

Radiopharm Theranostics presents a compelling value proposition for investors, characterized by several key factors:

  • Market Positioning: Radiopharm is strategically positioned to capture a significant share of the expanding theranostics market.
  • Diverse Product Pipeline: The company boasts a robust pipeline of radiopharmaceutical products targeting various oncological diseases, which diversifies risk and increases potential revenue streams.
  • Innovative Technology: Radiopharm’s focus on leveraging technological advancements in radiopharmaceuticals, particularly in treating oncological diseases, positions it at the cutting edge of medical innovation.
Radiopharm Theranostics partnership with Lantheus

Lantheus’ investment in Radiopharm marks a pivotal moment for both companies and holds substantial implications for the field of theranostics. The funding will facilitate Radiopharm’s research and development efforts, accelerating its product pipeline and market presence. Under the agreement, Radiopharm will transfer two early preclinical assets to Lantheus for a further AU$3 million, fostering a collaborative relationship focused on radiopharmaceutical development. The collaboration positions Radiopharm to capitalize on the increasing demand for theranostic solutions, aligning with trends in personalized medicine. Moreover, this financial backing will support clinical trials and operational needs, while also aiming for the commercialization of their products.

Company Highlights

  • Radiopharm Theranostics is focused on developing and commercializing radiopharmaceutical products and nuclear medicines for both therapeutic and diagnostic applications in precision oncology.
  • Radiopharm has four licensed platform technologies – nanobody, peptide, small molecules and monoclonal antibodies (mAb) – with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development.
  • The company has received clearance from the US Food and Drug Administration for an investigational new drug application with two INDs (one for RAD 301 and one for RAD 101). Phase 1 for RAD 301 and for RAD 204 is in progress.
  • The company aims to commercialize its pipeline for possible licensing and distribution agreements and has secured four platform technologies, which it is seeking to develop for the diagnosis and treatment of certain cancers.
  • Radiopharm owns 75 percent interest in Radiopharm Ventures, a joint venture created with The University of Texas MD Anderson Cancer Center.

Technology and Clinical Pipeline

Radiopharm has four licensed platform technologies – nanobody, peptide, small molecules and monoclonal antibodies (mAb) – with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development.

Radiopharm Theranostics imaging process

Radiopharm’s clinical stage development in the pipeline include:

  1. PD-L1 (non-small cell lung cancer indication) – currently in phase 1 in Australia;
  2. HER2 (breast/gastric cancer indication) – will begin phase 1 trials this year;
  3. Integrin VB6 (pancreatic cancer indication) – now in Phase I imaging in pancreatic cancer.
  4. Fatty Acid Synthase (brain METS indication) – preclinical has been completed and with IND approval for Phase IIb Imaging

The company recently received FDA approval for its investigational new drug application for 18-Pivalate (RAD 101). Labelled with the radioisotope F18, Pivalate is a small molecule that targets fatty acids synthase, which is overexpressed in brain tumours but not in normal cells.

Positive data from the company’s Phase 2 imaging trial of 17 patients with brain metastases has shown significant tumour uptake. Radiopharm holds an exclusive global license for the Pivalate platform.

Radiopharm Theranostics cancer cell targeting with Pivalate

Radiopharm highlights that Pivalate is potentially a new target for radiopharmaceutical brain imaging agents, and its unique mechanism of action may offer eligible patients a better option in relation to current imaging technology, which has many limitations.

Management Team

Paul Hopper – Executive Chairman

Paul Hopper is the founder of Radiopharm Theranostics. He has over 25 years of experience in the biotech, healthcare and life sciences. Focused on start-up and rapid-growth companies, he has served as the founder, chairman, non-executive director or CEO of more than 15 companies in the US, Australia and Asia. Previous and current boards include Imugene, Chimeric Therapeutics, Viralytics, Prescient Therapeutics and Polynoma. His experience covers extensive fund raising in US, Australia, Asia and Europe, and he has deep experience in corporate governance, risk management, and strategy.

Riccardo Canevari – Managing Director and Chief Executive Officer

Riccardo Canevari has broad and deep experience across specialty pharma, oncology and radiopharmaceuticals. He was most recently chief commercial officer of Novartis Advanced Accelerator Applications, one of the leading radiopharmaceutical and nuclear medicine companies, globally. He was responsible for global commercial strategy and country organizations in ~20 countries across North America, Europe and Asia. He was responsible for Lutathera’s in-market growth strategy and execution to build a blockbuster asset and for the pre-launch plan for Lu-PSMA 617 in metastatic prostate cancer. Prior to this, Canevari was senior vice-president and global head, breast cancer franchise for Novartis Oncology since 2017, overseeing the launch of major breast cancer products, including KISQALI and PIQRAY. He also held various management roles with Novartis Pharma and Ethicon/Johnson & Johnson.

Dr. Sherin Al-Safadi – Vice-president, Medical Affairs

Dr. Sherin Al-Safadi is an accomplished industry leader with many years of experience in pharmaceuticals and biotech. Most recently she was vice-president – medical affairs at POINT Biopharma, where she led the strategic and tactical planning for Phase III support and launch preparation of radiopharmaceuticals. She also provided strategic input and leadership for business development and licensing opportunities. She currently serves as co-founder and president at Foundation Amal (Canada-USA), overseeing an executive leadership team of 12 directors and members, who led the successful 2021 cross-border expansion into the USA and spearheaded the development of a successful branding and communication strategy. Al-Safadi holds a PhD in neurobiology from Concordia University, an MBA in entrepreneurship & management from the John Molson School of Business, and a MSc in pharmacology (oncology drug development) from McGill University.

Vimal Patel – Vice-president, CMC

Vimal Patel joins RAD from Orum Therapeutics where he was vice-president, head of CMC and supply chain. He was responsible for all CMC functions including process and analytical development, manufacturing, quality control, quality assurance, regulatory and supply chain. He led the successful manufacture of two ADCs and contributed to filing an IND leading to a Phase-I trial. Prior to Orum, Patel held roles of increasing responsibility in process development and manufacturing sciences at several companies, including Actinium Pharmaceuticals. Patel also held a position at Pfizer where he contributed to the refiling of Mylotarg and the filing of Besponsa BLAs. He also developed manufacturing processes for various ADCs. He also held roles at Daiichi Sankyo, Progenics Pharmaceuticals and SibTech in various capacities. Patel has MS in biotechnology from University of Connecticut and B.S. in chemical engineering from Sardar Patel University.

Noel Donnelly – Non-executive Director

Noel Donnelly brings more than 25 years of leadership experience in finance, strategy and operations within the biopharmaceutical and biotechnology industries. He has a distinguished track record of building and leading cross-functional teams, driving corporate governance and executing complex financial strategies that support rapid company. growth. Donnelly is current the chief financial officer of PepGen, where he oversaw the company’s financial strategy through its successful IPO, raising U$120 million and leading subsequent financial efforts that secured an additional US$90 million. Donnelly was previously the CFO of EIP Pharma (now, CervoMed), where he led the company’s IPO plannig phase. He had a 15-year tenure at Takeda/Shire PLC, in various senior roles, where he led critical R&D integrations and oversaw more than US$160 billion in integration planning and execution. He was instrumental in shaping the company’s portfolio management strategy.

This post appeared first on investingnews.com

Disney, Fox and Warner Bros. Discovery have called off plans to launch their sports streaming service, Venu, the companies said in a joint statement Friday.

“After careful consideration, we have collectively agreed to discontinue the Venu Sports joint venture and not launch the streaming service,” they said in the statement. “In an ever-changing marketplace, we determined that it was best to meet the evolving demands of sports fans by focusing on existing products and distribution channels. We are proud of the work that has been done on Venu to date and grateful to the Venu staff, whom we will support through this transition period.”

Venu was first announced in February and intended to combine the live sports assets of Fox, WBD and Disney-owned ESPN. It was initially slated to launch before the start of the NFL season in September, but was delayed in part by a legal challenge from internet TV bundler Fubo, which claimed the platform would be anticompetitive.

Together Disney, Fox and WBD control more than 50% of all U.S. sports media rights, and at least 60% of all nationally broadcast U.S. sports rights, according to the judge on the antitrust case.

The news that it would not launch came as a shock to Venu employees, who found out late Thursday night, according to people familiar with the matter. They believed they had a pathway forward to launch the service after Disney agreed earlier this week to merge its Hulu+ Live TV with Fubo, settling all litigation over Venu.

But the judge’s response in Fubo’s lawsuit questioned the legality of cable bundling in general, prompting Disney to strike the deal with Fubo, through which Disney would take 70% control of the resulting company. And two days ago, satellite providers DirecTV and Dish sent letters to federal court arguing that the legal questions brought up by the judge remained unanswered.

Rather than risk an extended lawsuit that could jeopardize bundling in general — including Disney’s efforts to bundle its own streaming entities (ESPN, Hulu and Disney+) — the three companies decided to pull the plug on Venu, according to people familiar with the company’s decisions.

Warner Bros. Discovery’s business model relies heavily on negotiating bundled carriage agreements for its many cable networks, including CNN, TNT, HGTV and Food Network.

Disney is targeting a debut of ESPN “Flagship,” an all-inclusive ESPN streaming service, for August 2025. The still unnamed ESPN streaming service will including everything that airs on ESPN’s linear network, unlike ESPN+.

Disney’s deal with Fubo, along with the company’s recent carriage renewal with DirecTV, also gives the company new ways to package so-called skinny bundles — narrower selections of channels for less money. This was the idea behind Venu: selling a smaller number of linear channels for less money than traditional cable TV.

Disclosure: Comcast, which owns CNBC parent NBCUniversal, is a co-owner of Hulu.

This post appeared first on NBC NEWS

Aides for Tesla and Space X CEO Elon Musk and tech entrepreneur Vivek Ramaswamy are starting to interview staffers with the federal government for the newly created Department of Government Efficiency (DOGE), according to a new report. 

Representatives for DOGE have had conversations with staffers from more than a dozen federal agencies — including the Treasury Department and the Internal Revenue Service, as well as the Departments of Veterans Affairs, Homeland Security, and Health and Human Services, The Washington Post reported Friday. 

Musk and Ramaswamy are leading DOGE, a blue-ribbon committee separate from the federal government that seeks to address issues concerning government spending, waste, efficiency and operations. They are expected to suggest executive actions for the Trump administration and partner with the Office of Management and Budget (OMB) to initiate reforms. 

Altogether, the committee aims to cut $2 trillion from the federal government budget through efforts to slash spending, government programs and the federal workforce. 

However, Musk recently cast doubt on the likelihood of eliminating $2 trillion from the federal budget and said there was a better chance at cutting $1 trillion. 

‘I think we’ll try for $2 trillion. I think that’s like the best-case outcome,’ Musk said during tech trade show CES on Wednesday in Las Vegas, the Post reported. ‘But I do think that you kind of have to have some overage. I think if we try for $2 trillion, we’ve got a good shot at getting $1 [trillion].’

Lawmakers on Capitol Hill have voiced support for working with DOGE, and Reps. Aaron Bean, R-Fla., and Pete Sessions, R-Texas, announced the creation of the Delivering Outstanding Government Efficiency (DOGE) Caucus last year. 

‘Our national debt has surpassed a staggering $36 trillion and should be a wakeup call for all Americans,’ House DOGE Caucus Co-Chair Bean said in a statement in November. ‘We must take action to avoid diving headfirst off the cliff of fiscal ruin. I’m thrilled with President-elect Trump’s appointment of Elon Musk and Vivek Ramaswamy to lead DOGE, but taking on Crazy Town will be no easy task — they will need partners.’

Likewise, Sen. Joni Ernst, R-Iowa, is slated to oversee the Senate DOGE Caucus.

‘The tables are finally turning, the knives are out, and waste is on the chopping block,’ Ernst said in a November statement. 

Currently, DOGE boasts a staff of approximately 50 people who are working from SpaceX’s offices in Washington, D.C., and it is aiming to roughly double that number when President-elect Trump is sworn into office on Jan. 20, according to the Post. 

A representative for Ramaswamy declined to provide comment to Fox News Digital.

DOGE appears to be the source of inspiration for other similar initiatives at the state level. For example, Republican Gov. Kelly Ayotte of swing state New Hampshire on Thursday announced the creation of the Commission on Government Efficiency, known as COGE.

‘COGE will make us smarter than ever before when it comes to saving taxpayer dollars and finding better ways to serve the people of our state,’ Ayotte said in her inaugural address. 

This post appeared first on FOX NEWS

Tulsi Gabbard, who is President-elect Donald Trump’s choice to be Director of National Intelligence (DNI) in his next administration, has reversed course on a controversial item after lobbying from Republican senators. 

Gabbard revealed on Friday that she believes section 702 of the Foreign Intelligence Surveillance Act (FISA) ‘is crucial for gathering foreign intelligence on non-U.S. persons abroad.’

She previously opposed FISA section 702 re-authorization while serving as a Democrat in the House of Representatives. 

‘We have a very important responsibility to strike a balance between national security to keep the American people safe, while also protecting our constitutionally protected freedoms,’ she said on the House floor in 2018. ‘Let us make this critical choice. Vote to keep our country safe. Vote to uphold our constitutional rights that so many have fought and died to protect.’

In her statement, provided by a Trump transition spokesperson, Gabbard said, ‘This unique capability cannot be replicated and must be safeguarded to protect our nation while ensuring the civil liberties of Americans.’

‘My prior concerns about FISA were based on insufficient protections for civil liberties, particularly regarding the FBI’s misuse of warrantless search powers on American citizens. Significant FISA reforms have been enacted since my time in Congress to address these issues. If confirmed as DNI, I will uphold Americans’ Fourth Amendment rights while maintaining vital national security tools like Section 702 to ensure the safety and freedom of the American people,’ she said. 

The change in Gabbard’s beliefs on the key national security issue was first reported by Punchbowl News. 

It comes after multiple Republican senators made the case to her of the importance of FISA’s section 702. 

Sen. Tom Cotton, R-Ark., chair of the Senate Select Committee on Intelligence, told Fox News Digital in a statement: ‘Tulsi Gabbard has assured me in our conversations that she supports Section 702 as recently amended and that she will follow the law and support its reauthorization as DNI.’

One GOP aide shared that during his meeting with Gabbard, Sen. James Lankford, R-Okla., emphasized how important the authority granted by section 702 is, and how important her navigation of it would be. 

In a podcast appearance earlier this week, Lankford told the Wall Street Journal’s Kim Strassel that there were some issues ‘that people aren’t talking about’ as it relates to Trump’s picks. One of them, he said, was Gabbard and her stance on section 702. 

‘She has voted against what’s called 702 authority every time that she was in Congress and voted against it. Well, now she’s going to be the spokesman for 702 authority. It’s a legitimate question just to say, ‘Okay, how are you going to handle this?’’ he asked. 

Lankford suggested that this is something that matters to other Republican senators. ‘I don’t hear anyone really coming up publicly and saying, ‘I’m adamantly opposed” to Trump’s nominees, he explained. 

But, ‘What I hear is a lot of people saying, ‘Hey, I want to give a fair hearing. I want people to be able to answer questions publicly.’’ 

While most GOP senators are supportive of FISA, some have been vocal critics. ‘Voting to reauthorize FISA 702 without a warrant requirement is difficult to defend. So are those casting such votes—especially if they purport to care about the Fourth Amendment,’ Sen. Mike Lee, R-Utah, wrote on X ahead of the most recent FISA re-authorization. 

Another top critic, Sen. Rand Paul, R-Ky., said in 2023, ‘Using 702, Americans’ communications content and metadata is inevitably swept up and kept in government databases without a warrant. Law enforcement agencies then access Americans’ communications without a warrant.’ 

These Republicans may not be as happy about Gabbard’s change of heart. However, there isn’t any indication that it would harm their support for her as of yet. 

One Republican senate source cast doubt on Gabbard’s new stance, noting that she has been ‘a life-long skeptic of intelligence gathering.’ They suggested it is unlikely that she has ‘completely changed her mind.’ 

A GOP Senate source confirmed to Fox News Digital that conservative senators are encouraged by Senate Majority Leader John Thune, R-S.D., and his apparent desire to confirm Trump nominees on the day he is sworn into office. 

The group is eager to have all national security nominees confirmed on Trump’s first day, they added. 

This post appeared first on FOX NEWS

Democratic lawmakers were noticeably silent following the sentencing of President-elect Donald Trump despite previously commenting on the cases against him, as Washington prepares for a Republican trifecta in Congress.

Trump was sentenced on Friday after being found guilty on 34 charges related to falsifying business records in May.

The incoming president was sentenced to unconditional discharge, which means that he will not receive any jail time, fine or probation time. The sentence also preserves Trump’s ability to appeal the conviction. 

After Trump was found guilty in criminal court in May, Democratic members of Congress put out a flurry of reactions on social media but appeared mum after the sentencing on Friday, which comes just days before he will be sworn into office on Jan. 20. 

House Minority Leader Hakeem Jeffries, D-N.Y., in May, wrote in a post on X, fomerly Twitter, that ‘the jury has spoken and carefully rendered a decision. Responsible leadership requires the verdict to be respected,’ while Rep. Alexandria Ocasio-Cortez of New York said that ‘nobody is above the law.’

However, Democrats appeared less reactive to Friday’s sentencing, which left Trump free of any penalty.

One Democratic congresswoman put out a statement following the unconditional discharge sentence, claiming that ‘our system of justice is not just.’

‘There is a two-tiered system of justice in this country, and Donald Trump lives on the tier where he gets to walk into the White House without spending a single day in jail or being put on probation after being convicted of 34 felonies. On the other tier are the clients I represented as a public defender in Texas, like the seventeen-year-old boy who was held on felony probation for taking some candy from his school’s concession stand,’ Rep. Jasmine Crockett, D-Texas, said in a post on X. 

‘The scales are not equal,’ she added.

On the flip side, Republicans were very vocal following the sentencing. 

‘I have no respect for the process being used in New York. I find the judge and prosecutor’s motives to be dripping with politics,’ Sen. Lindsey Graham, R-S.C., said in a statement. ‘This is a sad day for America.’

Trump, ahead of the sentencing, said that he would appeal the decision.

Trump filed an emergency petition to the Supreme Court on Wednesday in an effort to prevent his Jan. 10 sentencing, but the high court ultimately denied his emergency petition to block his sentencing.

Fox News’ Brooke Singman contributed to this report.

This post appeared first on FOX NEWS